Phase II trial of cannabidiol for Parkinson's psychosis - King's College London
£1.2 million over 42 months (currently active)
A 6-week pilot and 12-week double, blind placebo-controlled trial to provide preliminary evidence for the safety and efficacy of cannabidiol (CBD) capsules for the treatment of Parkinson's-related psychosis.
Novel mitochondrial rescue compounds - University of Sheffield
£98,000 over 12 months (currently active)
Screening and in vitro testing programme to identify compounds that rescue mitochondrial function with reduced off-target effects.
Novel mPTP inhibitors - NRG Therapeutics
£1 million over 12 months (currently active)
A preclinical programme to discover and develop a potential drug that could safeguard the dopaminergic cells damaged by Parkinson's and slow down the progression of the condition.
Novel gene transcription modulators - Eurofins Selcia Drug Discovery
£2.5 million over 24 months (currently active)
A drug discovery and development programme to create molecules that increase the activity of genes to increase dopamine synthesis and boost the production of neuroprotective proteins.
Serotonin 5-HT1A receptor agonist, NLX-112 - Neurolixis
£780,000 over 15 months
This project supported the final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
Novel Nrf2-KEAP1 inhibitors - Keapstone Therapeutics Limited
£2.3 million over 28 months
A drug discovery and development programme that developed and optimised novel inhibitors of the interaction between NFE2-related factor 2 (Nrf2) and Kelch-like ECH associated protein 1 (KEAP1).
Glial cell line-derived neurotrophic factor - Medgenesis Therapeutics Inc.
£2.5 million over 62 months
A placebo-controlled, randomised, double-blind trial that assessed the safety and efficacy of intermittent bilateral intraputamenal glial cell line-derived neurotrophic factor (GDNF) infusions administered via convection enhanced delivery (CED) in subjects with Parkinson’s disease.